相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2022)
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
Luca Gianni et al.
NPJ BREAST CANCER (2022)
Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+HER2+breast cancer (PALTAN)
Foluso O. Ademuyiwa et al.
CANCER RESEARCH (2022)
Systemic Therapy for Advanced Human 3 Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
Jian Zhang et al.
FRONTIERS IN ONCOLOGY (2022)
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2021)
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
Ming Zhao et al.
CLINICAL CANCER RESEARCH (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens
Shumei Kato et al.
JCI INSIGHT (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
Loredana Urso et al.
FRONTIERS IN ONCOLOGY (2021)
Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2021)
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
Laura M. Spring et al.
NPJ BREAST CANCER (2021)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms
Margaretha A. Skowron et al.
BRITISH JOURNAL OF CANCER (2020)
An update on the implications of cyclin D1 in melanomas
Lucia Gonzalez-Ruiz et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Qi Du et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney et al.
LANCET ONCOLOGY (2020)
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2020)
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Aena Patel et al.
CANCERS (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Eva Ciruelos et al.
CLINICAL CANCER RESEARCH (2020)
Screening of Polymer-Based Drug Delivery Vehicles Targeting Folate Receptors in Triple-Negative Breast Cancer
Dola Das et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2020)
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
Tanja K. Eggersmann et al.
BIODRUGS (2019)
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
Oscar M. Rueda et al.
NATURE (2019)
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
Shom Goel et al.
CLINICAL BREAST CANCER (2019)
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
Gaia Giannone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tucatinib, palbociclib, and letrozole in HR+/HER2+metastatic breast cancer: Report of phase IB safety cohort.
Elena Shagisultanova et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
An-Chi Tien et al.
CLINICAL CANCER RESEARCH (2019)
HER2 and Breast Cancer - A Phenomenal Success Story
Daniel F. Hayes
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Role of the Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway in Ischemia-Reperfusion Injury
Tingting Kong et al.
FRONTIERS IN PHYSIOLOGY (2019)
286TiPPhase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) breast cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
L Biganzoli et al.
ANNALS OF ONCOLOGY (2019)
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
Ana Godoy-Ortiz et al.
FRONTIERS IN ONCOLOGY (2019)
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Sarah Croessmann et al.
CLINICAL CANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra et al.
NPJ BREAST CANCER (2019)
Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies
Louisa A. Mounsey et al.
CLINICAL BREAST CANCER (2018)
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
Luca Gianni et al.
LANCET ONCOLOGY (2018)
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Neil O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Alexey A. Larionov
FRONTIERS IN ONCOLOGY (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Targeting the cell cycle in breast cancer: towards the next phase
K. L. Thu et al.
CELL CYCLE (2018)
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR plus with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.
Patricia Villagrasa et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
369TiPPATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)
S Loibl et al.
ANNALS OF ONCOLOGY (2018)
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Sunkyu Kim et al.
Oncotarget (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Cell cycle regulation and anticancer drug discovery
Jingwen Bai et al.
CANCER BIOLOGY & MEDICINE (2017)
Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer.
Bilal ElChaarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Breast cancer statistics, 2017, racial disparity in mortality by state
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
Debu Tripathy et al.
CLINICAL CANCER RESEARCH (2017)
CDK4/6 inhibitors in HER2-positive breast cancer
Silvia Paola Corona et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto et al.
NATURE REVIEWS CANCER (2017)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Shom Goel et al.
CANCER CELL (2016)
HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes
Bryan C. Nikolai et al.
CANCER RESEARCH (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
Xiaoling Song et al.
CANCER RESEARCH (2015)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Mario Giuliano et al.
CLINICAL CANCER RESEARCH (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub et al.
DRUG METABOLISM AND DISPOSITION (2015)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context
Fabienne Schmit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity
Patrizia Bonelli et al.
BIOMED RESEARCH INTERNATIONAL (2014)
HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients
Soo Youn Bae et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2013)
HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling
Z. Hartman et al.
ONCOGENE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
Rita Nahta et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
Bivalent binding drives the formation of the Grb2-Gab1 signaling complex in a noncooperative manner
Caleb B. McDonald et al.
FEBS JOURNAL (2012)
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Patrick J. Roberts et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
Karine Michaud et al.
CANCER RESEARCH (2010)
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
Stuart J. Schnitt
MODERN PATHOLOGY (2010)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
The epidermal growth factor receptor family: Biology driving targeted therapeutics
M. J. Wieduwilt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
p21 and p27: roles in carcinogenesis and drug resistance
Abde M. Abukhdeir et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
RB and cell cycle progression
C. Giacinti et al.
ONCOGENE (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cell cycle genes in ovarian cancer: Steps toward earlier diagnosis and novel therapies
G D'Andrilli et al.
CLINICAL CANCER RESEARCH (2004)
Analysis of cell cycle regulator proteins in non-small cell lung cancer
V Esposito et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
F Chang et al.
LEUKEMIA (2003)
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
J Liang et al.
NATURE MEDICINE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The Rb/E2F pathway: expanding roles and emerging paradigms
JW Harbour et al.
GENES & DEVELOPMENT (2000)
分享论文
